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Abstract
Purpose—Toxoplasmosis, caused by the parasite Toxoplasma gondii, can have serious impacts 
on fetal development in the setting of acute maternal primary infection. The U.S. Centers for 
Disease Control and Prevention and the American College of Obstetricians and Gynecologists 
(ACOG) sought to determine current knowledge, practices, opinions and educational preferences 
regarding T. gondii infection in pregnancy among ACOG members practicing prenatal care.
Methods—A survey was sent to 1056 ACOG members chosen by stratified random sampling 
from membership lists, including 370 participants and 686 non-participants in the Collaborative 
Ambulatory Research Network (CARN). Mailings were sent up to 4 total times to nonresponders.
Results—Minimum response rates were 40.3% (CARN) and 19.7% (non-CARN); responses 
rates adjusted for imputed non-eligibility were 59.7% (CARN) and 22.6% (non-CARN). Among 
providers, 80.2% had diagnosed no acute maternal T. gondii infections in the past 5 years, 12.7% 
correctly identified the screening role of the Toxoplasma avidity test, 42.6% routinely performed 
serologic T. gondii screening for at least some asymptomatic pregnant women, and 62.1% of those 
who so did used appropriate approaches. Providers in the northeastern United States were 2.02 
times more likely to routinely screen than those in the west (p=.025) and female providers were 
1.48 times more likely than male providers (p=.047). The potential educational interventions 
considered useful by the most practitioners were updated ACOG guidelines on screening (81.4%) 
and management (71.7%) for acute T. gondii infection in pregnancy.
Conclusions—ACOG members would benefit from educational efforts targeted at risk factor 
counseling and screening approaches.
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Acute Toxoplasma gondii infection in pregnant women can cause serious sequelae in their 
infants. If transplacental transmission causes fetal infection, neurologic and ocular birth 
defects can result. However, with early maternal diagnosis, treatment regimens are available 
that may decrease risk of transplacental transmission, or reduce clinical manifestations if 
transmission occurs. Due to the lack of well-controlled studies, though, the efficacy of these 
treatments and the utility of routine screening remain controversial. In the United States 
there are no universally accepted guidelines, and practice varies.
The US Centers for Disease Control and Prevention (CDC) and the American College of 
Obstetricians and Gynecologists (ACOG) conducted surveys of obstetrical providers in 1998 
[1] and 2006 [2]. These identified educational needs later addressed in an ACOG practice 
bulletin [3]. In 2012, we circulated a third updated survey to the ACOG membership to 
follow changes in practitioner knowledge, practices and opinions. Here we report results.
Materials and Methods
A questionnaire was developed with reference to the prior surveys, and pilot-tested by 
ACOG. It addressed experience, knowledge and practices regarding screening, diagnosis 
and management of acute maternal and fetal toxoplasmosis; and opinions on legislative 
regulation of screening and continuing education needs. Demographic characteristics, 
practice type and patient population were also collected. Participants were selected from 
among ACOG members, including both non-participants and participants in ACOG's 
Collaborative Ambulatory Research Network (CARN), a cadre of practicing obstetrician-
gynecologists who have agreed to participate in periodic ACOG surveys.
Stratified random sampling was used to sort ACOG and CARN members into groups of 100, 
balanced on age, gender and geography, minus losses due to invalid addresses or 
discontinued practice. Then groups were randomly selected to total a similar target 
respondent number to previous ACOG surveys. In 2012-2013, the questionnaire was mailed 
(including four mailings to nonresponders) to 1056 ACOG members (370 CARN members, 
686 non-CARN). Analysis was performed using SAS Enterprise Guide version 9.3 (SAS 
Institute, Cary, NC). Respondent surveys were included if their CARN affiliation was 
known, they answered more than three survey questions, and they were currently practicing 
obstetrics including prenatal care. US Census regions [4] were used to delineate practice 
regions.
Responses were analyzed separately for CARN and non-CARN respondents. Denominators 
vary because not all respondents answered all questions. Results are for total proportion of 
respondents selecting a given answer; for questions for which multiple answers were 
accepted, totals may therefore exceed 100%. Answer proportions were compared between 
groups using the Fisher's exact test for categorical variables and a two-sample t-test for 
continuous variables. If not significantly different, groups were pooled to calculate total 
proportions giving each answer, for which 95% Clopper-Pearson confidence intervals (CIs) 
were calculated; otherwise, proportions were calculated for each group separately.
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Univariate Poisson regression models were used to investigate the association between 
selected outcome variables -- ever performing serologic screening on pregnant women, 
correctly identifying letting a pet cat go outdoors and gardening as risk factors, and using an 
“acceptable”a seroscreening method -- and covariates including provider gender, years 
elapsed since completing residency, primary practice field, and geographic region. If more 
than one covariate was associated with a given outcome, multivariate Poisson regression 
using all covariates significant at alpha =.05 on univariate analysis (forward stepwise 
approach) was performed for that outcome. P-values are provided, allowing assessment of 
significance at either p<.05, or p < .0125 after adjusting for multiple comparisons.
The study was reviewed and exempted by ACOG and CDC human subjects committees.
Results
Response rate
The participant flowchart, including response rates, is in Figure 1. The minimum response 
rates were: 40.3% CARN, 19.7% non-CARN; if nonrespondents were ineligible in the same 
proportion as respondents, however, response rates were: 59.7% CARN, 22.6% non-CARN.
Respondent demographics
Respondents had been practicing for a mean of 21.0 years. Mean age was 52.7 years in 2012 
(95% CI 51.6-53.1); mean years in practice were 21.0 (95% CI 19.8-22.0). Other 
characteristics are in Table 1. Only in gender were CARN and non-CARN respondents 
different (p=0.04; CARN percent male = 41.9, 95% CI 34.1-50.1; non-CARN, 50.8%, 95% 
CI 41.5-60.2).
Other significant differences between CARN and non-CARN respondents were uncommon 
and are noted below.
Provider Experience
Answers to questions about provider experience and the other topics that follow are shown 
in table 2, except where covered in the text. Where applicable, correct answers are marked 
in the table with the footnote: a. Providers had diagnosed few cases of acute maternal 
toxoplasmosis, with 80.2% diagnosing none, and only 5.4% over one, in the past five years.
Risk Factors and Counseling
Most respondents (73.8%) provided prenatal toxoplasmosis counseling at the first visit, 
including 30.0% when the patient asked questions and 25.5% when they considered the 
patient high-risk. Well-recognized risk factors included changing cat litter without gloves 
(95.1%), contact with sand from an uncovered sandbox (78.9%), and eating raw or 
undercooked meat (83.3%). Less-known factors included changing cat litter every few days 
compared to daily (54.1%), having a litter of kittens at home (21.2%), and gardening 
a“Acceptable” screening methods included checking both IgG and IgM; checking IgG alone repeatedly (allowing ascertainment of 
seroconversion); or checking IgM if then confirmed with IgM and IgG.
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without gloves or employment involving soil exposure (61.5%, 57.3%, respectively). feces). 
Among providers who considered an exposure a risk factor, prevalence of including it in 
counseling varied (39.1-97.3%).
Among those who identified gardening without gloves as a risk factor, CARN and non-
CARN providers were significantly (p= .04) more likely to include it in counseling.
Overall, 6.4% of providers answered four or fewer risk factor questions correctly, 40.1% 
five to eight, 47.9% nine to twelve, and 5.6% more than 12. Among providers answering 
nine or more questions correctly, often-missed risk factors were eating raw or undercooked 
oysters, mussels or clams (35.8%); eating unwashed raw fruits or vegetables (55.0%); and 
drinking untreated water from a stream, lake or pond (55.0%).
Screening and Diagnosis
Forty-two point six percent of providers (95% CI 36.7%-48.6%) reported ever seroscreening 
for acute T. gondii infection in asymptomatic pregnant women. Of these, 55.6% reported 
deciding who to screen by asking about risk factors; 27.8% also required absence of a 
previous positive serology. Respondents who seroscreened generally did so once, either as 
early as possible (70.5%; 95% CI 64.9%-80.2%) or if indicated by signs/symptoms or 
exposure (16.0%; 95% CI 10.2%-23.5%).
Providers’ mean estimate of the laboratory cost of their screening approach was $182.50. 
CARN providers estimated significantly (p=.02) higher costs ($224.17, 95% CI $163.17- 
$285.16 compared to $126.94, 95% CI $80.95- $172.94). Of providers who ever 
seroscreened asymptomatic pregnant women, 59.1% (95% CI 50.7%-67.5%) used T. gondii 
IgG and IgM (estimating a mean cost of $199.35); 24.2% (95% CI 17.2%-34.5%) IgG only 
(with or without “T. gondii titer”, a term interpretable as referring to tests which do not 
discriminate between IgG and IgM); 2.3% (95% CI 0.5%-6.5%) IgM only (with or without 
“T. gondii titer”), 7.6% (95% CI 3.7%-13.5%) “T. gondii titer” only, 0.8% (95% CI 
0.0%-4.2%) IgA, and 6.1% (2.7%-11.6%) did not know.
Among approaches to confirmation, most common were answers containing both IgG and 
IgM (20.8%), T. gondii titer only (8.0%), and ‘don't know’ (24.6%); 46.6% took other 
approaches. Toxoplasma avidity was included by 9.7%. Eleven point one percent of 
respondents would send confirmatory testing (vs 1.9% initial testing) to the Palo Alto 
Research Institute's Toxoplasma Serology Laboratory, a nonprofit institution offering expert 
testing.
Approach to Acute Maternal and Fetal T. gondii infection
Given a diagnosis of acute maternal T. gondii infection at 14 weeks or 23 weeks gestation, 
most providers (92.0% and 93.6% respectively) would consult a specialist. Fewer would 
begin antimicrobial therapy (14.4% and 8.6%) or perform amniocentesis (7.6% and 9.5%). 
For fetal toxoplasmosis, 84.4% would consult with an infectious disease specialist, 11% 
begin antimicrobial treatment, 10.3% perform immediate fetal ultrasound, and 0.8% 
recommend termination. In the case of acute maternal infection at 14 weeks, CARN 
respondents were significantly more likely (p=.01) to begin antimicrobial therapy.
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Provider knowledge about toxoplasmosis testing options
Most respondents were not sure which screening test gives frequent false positives (62.1%; 
IgM is correct); or false negatives (70.9%; no widely used test is correct). Only 7.2% 
correctly stated that the effectiveness of spiramycin against maternal-fetal T. gondii 
transmission is unknown or controversial (51.3% did not know), and 12.7% that the 
Toxoplasma avidity test determines whether maternal T. gondii infection occurred in the last 
3-4 months. CARN members were significantly more likely (p=.03) to answer this question 
correctly.
Provider opinions on standardized screening approaches
Eighty-nine percent of respondents were opposed (1 or 2 on a 5-point scale) to universal 
monthly toxoplasmosis screening in pregnancy, 72% to universal screening once per 
trimester, and 43% to universal screening once in each pregnancy (with 34% in favor). 
Eighty-one percent favored screening only for patients with risk factors or recent clinical 
signs or symptoms, consistent with reported practice (see above). (Those favoring risk-
factor-based screening answered risk factor questions correctly in proportions similar to all 
respondents).
For the scenario of state-mandated universal monthly screening, often-cited benefits were 
improved patient knowledge about and avoidance of exposure to T. gondii risk factors 
(40.8%) and identification of toxoplasmosis infections without known risk factors (40.5%). 
Often-cited disadvantages were false-positive results leading to unnecessary workup and/or 
treatment with potential side effects (72.6%) or unnecessary anxiety (65.8%), and lack of 
evidence of cost-effectiveness (70.7%).
Provider sources of information
The most-cited sources of information on advances in OB/GYN infectious disease care used 
by respondents were ACOG publications (37.9% first choice; 82.8% among top 3 choices), 
followed by journals (24.1%; 53.1%) and UpToDate (14.6%; 43.4%); 53.4% also listed 
CME activities with any ranking. Sources favored by respondents (first, second or third 
choice) for ACOG to help physicians develop the skills to manage acute toxoplasmosis in 
pregnancy were updating ACOG guidelines on screening and management (81.4% and 
71.7% respectively), feature articles in newsletters (30.1%), CME monographs (26.4%) and 
online CME (20.3%).
Comparison with prior years
Ninety point four percent of 1998 respondents had diagnosed no acute cases of 
toxoplasmosis in the past year, compared to 92.1% (95% CI 88.8%-95.3%) of 2012 
respondents. Fifty-three point four percent of 2006 respondents compared to 73.8% (95% CI 
68.1%-79.0%) of 2012 respondents reported providing risk factor counseling at the initial 
pregnancy visit. When counseling, similar proportions of respondents included handling cat 
litter in 2012 and 2006 (92.5% and 99.6%); 41.9% and 65.4% respectively (compared to 
67.6% in 1998) included gardening. (In both cases the 2012 question added “without 
gloves”).
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While only 8.8% of 2006 respondents had heard of the Toxoplasma avidity test, 50.8% of 
those who had, and who identified an answer for the time frame for infection it suggested, 
answered correctly (the past 3-4 months); in comparison, 12.7% of all 2012 respondents 
identified time frame correctly, where 61.5% chose “don't know”.
Associative Analysis
Providers in the Northeast were 2.02 times (95% CI 1.31-3.72; p = .025) more likely than 
those in the West to ever screen for acute maternal toxoplasmosis in asymptomatic pregnant 
women (59.1% vs. 29.3%). Female providers were 1.48 times (95% CI 1.00-2.17; p=.047) 
more likely to do so than male providers (63.1% vs. 42.6%). With both covariates included, 
region remained significant (1.98; 95% CI 1.30-3.67; p = .028); gender did not (1.45; 95% 
CI 0.98-2.15; p = .062). Other associations were not significant.
Discussion
Fetal toxoplasmosis is an uncommon but potentially serious complication of pregnancy. An 
estimated 89% of women of childbearing age are susceptible to acute T. gondii infection 
(not previously infected) [5], with roughly 400—4000 [6-9] newborns born with congenital 
T. gondii infection annually in the United States.
An increasing majority of obstetricians counsel pregnant women about risk factors for 
toxoplasmosis. While exposures from cat litter, sandboxes and raw meat were well-
recognized, other risk factors for transmission via domestic cats, gardening, travel without 
food and water precautions, and soil exposure were less recognized. This is important given 
the importance of outdoor exposure of domestic cats [10], soil exposure [11] and travel [12] 
as risk factors for infection. Awareness of the Toxoplasma avidity test remains uncommon. 
Availability of comparison over time was limited by the substantial changes in the 2012 
survey compared to prior years, but practitioner knowledge about toxoplasmosis does not 
appear to have increased substantially.
Changing cat litter daily can virtually eliminate its potential for T. gondii transmission, as 
oocysts require 1-5 days to become infectious [13,14]. T. gondii from infected feces can 
survive in soil for over a year [15] and contaminate hands, fruits or vegetables, or water. 
Pregnant women can minimize exposure risks by eating only washed produce and when 
gardening, wearing gloves and washing hands afterward, removing dirt under the nails.
Roughly half of providers sometimes seroscreened asymptomatic pregnant women, most 
commonly based on risk factors; the most-preferred approach among our respondents was 
seroscreening only for patients with risk factors or recent signs or symptoms. For diagnoses 
of acute maternal T. gondii infection or fetal toxoplasmosis, respondents favored specialist 
consultation.
No approach to toxoplasmosis screening or management is universally endorsed. One expert 
group in the United States, Montoya et al. [16], recommends screening all pregnant women 
for IgG and IgM early in the first trimester; 59.1% of respondents who screened used both 
tests. Depending on results, this group recommends following up initial positive results by 
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retesting (for example, when IgG-negative, IgM-positive) or sending samples to the Palo 
Alto Medical Foundation Toxoplasma Serology Laboratory (IgG and IgM both positive), 
where Toxoplasma avidity testing may be used. Eleven point one percent of our survey 
respondents would send confirmatory testing to this laboratory.
Montoya et al.'s approach takes into account properties of the screening tests: IgM has a 
high false-positive rate (reported specificities range between 49.2% [17] and 98.6% [18,19]). 
A true positive indicates infection within the past 12-18 months (in some cases T. gondii 
IgM can persist for up to two years [20].) A true positive IgG result indicates infection at 
some point in the past; of questions about test characteristics, this was the only one 
answered correctly by most respondents.
In contrast, another expert group, Gilbert and others [21] and the Society of Obstetricians 
and Gynecologists of Canada (SOGC) [22], recommend screening only in cases of high 
suspicion, such as suggestive maternal symptoms or high-risk exposures (consistent with the 
answers of 87.4% of respondents). Several countries have considered but not adopted 
universal screening [.23—27] Reasons include both costs and such possible harms [28] such 
as unnecessary treatment due to overdiagnosis and pregnancy terminations. Followup has 
also proven challenging: late initial testing and poor compliance with screening intervals has 
led to delayed therapy in France [29] and Austria [30].
The Healthcare Blue Book cites $30 for physician-ordered Toxoplasma IgG testing and $35 
for Toxoplasma IgM as reimbursement levels typically accepted from insurers [31] - 
considerably lower than respondents’ estimates. Awareness of the Toxoplasma avidity test 
remains low. Often this test can help distinguish whether infection occurred in the past 3-4 
months [32-34], a useful feature for first-trimester diagnoses given the long persistence of 
IgM.
Most providers indicated they would seek expert help after diagnosing acute maternal T. 
gondii infection. This is a clearly reasonable approach. In such cases, they recommend fetal 
ultrasound as soon as possible and amniotic fluid PCR at 18 weeks gestation to determine 
fetal infection. If maternal infection was diagnosed before 18 weeks gestation, they 
recommend treatment begin with spiramycin until PCR and ultrasound results are available. 
Then, if either is positive, treatment switches to pyramethamine sulfadiazine and folinic acid 
(though others question its superiority to spiramycin for this or any indication); if negative, 
[22,35,36], spiramycin should be started or continued. If instead maternal infection is 
diagnosed after 18 weeks gestation, pyramethamine sulfadiazine and folinic acid are the 
default treatment until and unless PCR and ultrasound are negative, in which case either 
pyramethamine sulfadiazine with folinic acid or spiramycin can be continued untill delivery.
The efficacy of spiramycin, which most providers reported not knowing, is uncertain; 
comparisons with historical controls suggest benefit [37-39] while more recent 
nonrandomized studies [40] suggest it may decrease sequelae only [41,42]. Spiramycin is 
available in the United States from the FDA Division of Special Pathogen and Immunologic 
Drug Products under an Investigational New Drug license, at 301-827-2335.
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The higher prevalence of seroscreening asymptomatic pregnant women among providers in 
the U.S Northeast is consistent with an increased prevalence of toxoplasmosis exposure in 
this region [43] (29.2%, vs. 22.5% nationally in 1988-1994).
Limitations of our study include the use of self-reported data and the low survey response 
rates, all potentially causing overestimation of practitioner knowledge. The many 
comparisons between CARN and non-CARN respondents may have caused discovery of 
spurious differences. The Clopper-Pearson method may not fully account for any 
intracluster correlation within the provider groups in which survey recipients were selected, 
but given the method used for composing these groups, intracluster correlation should be 
minimal, with any resulting underestimation of variance also countered by using sandwich 
estimators for variance.
Continuing education for providers on T. gondii prevention, diagnosis, and treatment is 
needed. Updated ACOG guidelines addressing these issues would be of particular benefit. 
However, additional evidence is needed on the magnitudes of expected benefits, harms and 
costs of routine screening, and comparative effectiveness of alternative antibiotic regimens 
against maternal-fetal transmission and sequellae.
Acknowledgments
This study is funded in part by grant UA6MC19010, through the U.S. Department of Health and Human Services, 
Health Resources and Services Administration, Maternal and Child Health Research Program.
References
1. Jones JL, Dietz VJ, Power M, Lopez A, Wilson M, Navin TR, Gibbs R, Schulkin J. Survey of 
obstetrician-gynecologists in the United States about toxoplasmosis. Infect Dis Obstet Gynecol. 
2001; 9:23–31. [PubMed: 11368255] 
2. Jones JL, Krueger A, Schulkin J, Schantz PM. Toxoplasmosis Prevention and Testing in Pregnancy, 
Survey of Obstetrician–Gynaecologists. Zoonoses Public Health. 2009; 57:27–33. [PubMed: 
19744302] 
3. ACOG Practice Bulletin: Perinatal Viral and Parasitic Infections No. 20. Int J Gynecol Obstet. 2000; 
76:95–107.
4. US Census Bureau. [10 June 2013] Census Regions and Divisions of the United States. https://
www.census.gov/geo/www/us_regdiv.pdf.
5. Jones JL, Kruszon-Moran D, Sanders-Lewis K, Wilson M. Toxoplasma gondii infection in the 
United States, 1999–2004, decline from the prior decade. Am J Trop Med Hyg. 2007; 77:405–410. 
[PubMed: 17827351] 
6. Alford CA Jr, Stagno S, Reynolds DW. Congenital toxoplasmosis: clinical, laboratory, and 
therapeutic considerations, with special reference to subclinical disease. Bull N Y Acad Med. 1974; 
50:160–181. [PubMed: 4592095] 
7. Kimball AC, Kean BH, Fuchs S. Congenital toxoplasmosis: a prospective study of 4,048 obstetric 
patients. Am J Obstet Gynecol. 1971; 111:211–218. [PubMed: 5098590] 
8. Guerina NG, Hsu HW, Meissner HC, Maguire JH, Lynfield R, Stechenberg B, Abroms I, 
Pasternack MS, Hoff R, Eaton RB, Grady GF, New England Regional Toxoplasma Working Group. 
Neonatal serologic screening and early treatment for congenital Toxoplasma gondii infection. N 
Engl J Med. 1994; 330:1858–1863. [PubMed: 7818637] 
9. Lopez A, Dietz V, Wilson M, Navin TR, Jones JL. Preventing congenital toxoplasmosis. MMWR 
Recomm Rep. 2000; 49:37–75. [PubMed: 15580731] 
Davis et al. Page 8













10. Lopes AP, Cardoso L, Rodrigues M. Serological survey of Toxoplasma gondii infection in 
domestic cats from northeastern Portugal. Vet Parasitol. 2008 Aug 17. 2008; 155(3-4):184–9. doi: 
10.1016/j.vetpar.2008.05.007. 
11. Cvetković D1, Bobić B, Jankovska G, Klun I, Panovski N, Djurković-Djaković O. Risk factors for 
Toxoplasma infection in pregnant women in FYR of Macedonia. Parasite. 2010; 17(3):183–6. 
[PubMed: 21073139] 
12. Anand R, Jones CW, Ricks JH, Sofarelli TA, Hale DC. Acute primary toxoplasmosis in travelers 
returning from endemic countries. J Travel Med. 2012; 19:57–60. doi: 10.1111/j.
1708-8305.2011.00564.x. [PubMed: 22221813] 
13. Dubey JP. Toxoplasmosis. J Am Vet Med Assoc. 1994; 205:1593–1598. [PubMed: 7730132] 
14. Dubey JP, Miller NM, Frenkel JK. The Toxoplasma gondii oocyst from cat feces. J Exp Med. 
1970; 132:636–662. [PubMed: 4927658] 
15. Lélu M, Villena I, Dardé ML, Aubert D, Geers R, Dupuis E, Marnef F, Poulle ML, Gotteland C, 
Dumètre A, Gilot-Fromont E. Quantitative estimation of the viability of Toxoplasma gondii 
oocysts in soil. Appl Environ Microbiol. 2012; 78:5127–5132. [PubMed: 22582074] 
16. Montoya JG, Remington JS. Management of Toxoplasma gondii Infection during pregnancy. Clin 
Infect Dis. 2008; 47:554–566. [PubMed: 18624630] 
17. Liesenfeld O, Press C, Montoya JG, Gill R, Isaac-Renton JL, Hedman K, Remington JS. False-
positive results in immunoglobulin M (IgM) Toxoplasma antibody tests and importance of 
confirmatory testing: the Platelia Toxo IgM Test. J Clin Microbiol. 1997; 35:174–178. [PubMed: 
8968902] 
18. Wilson MJ, Remington S, Clavet C, Varney G, Press C, Ware D. Evaluation of six commercial kits 
for detection of human immunoglobulin M antibodies to Toxoplasma gondii. J Clin Microbiol. 
1997; 35:3112–3115. [PubMed: 9399504] 
19. Liesenfeld O, Press C, Montoya JG, Gill R, Isaac-Renton JL, Hedman K, Remington JS. False-
positive results in immunoglobulin M (IgM) Toxoplasma antibody tests and importance of 
confirmatory testing: the Platelia Toxo IgM Test. J Clin Microbiol. 1997; 35:174–178. [PubMed: 
8968902] 
20. Gras L, Gilbert RE, Wallon M, Peyron F, Cortina-Borja M. Duration of the IgM response in 
women acquiring Toxoplasma gondii during pregnancy: implications for clinical practice and 
cross-sectional incidence studies. Epidemiol Infect. 2004; 132:541–548. [PubMed: 15188723] 
21. Gilbert R, Petersen E. Toxoplasmosis and pregnancy. 2013 UptoDate Online. Accessed 16 October 
2013. 
22. Paquet C, Yudin MH. Toxoplasmosis in Pregnancy: Prevention, Screening, and Treatment. J 
Obstet Gynaecol Can. 2013; 35:78–79. [PubMed: 23343802] 
23. Peckham, C. [5 August 2013] Screening for toxoplasmosis. Expert review for United Kingdom 
policy. 2011. http://www.screening.nhs.uk/policydb_download.php?doc=138.
24. [5 August 2013] UK National Screening Committee policy on toxoplasmosis screening in 
pregnancy (updated December 2011). http://www.screening.nhs.uk/toxoplasmosis.
25. Rudin C, Boubaker K, Raeber PA, Vaudaux B, Bucher HC, Garweg JG, Hoesli I, Kind C, Hohlfeld 
P. Toxoplasmosis during pregnancy and infancy, a new approach for Switzerland. Swiss Med 
Wkly. 2008; 138(Suppl 168):1–8. [PubMed: 19475733] 
26. Röser D, Nielsen HV, Petersen E, Saugmann-Jensen P, Nørgaard-Pedersen PB. Congenital 
toxoplasmosis—a report on the Danish neonatal screening programme 1999–2007. J Inherit Metab 
Dis. 2010; 33(Suppl 2):S241–S247. [PubMed: 20585987] 
27. Miron D, Raz R, Luder A. Congenital toxoplasmosis in Israel: to screen or not to screen. Isr Med 
Assoc J. 2002; 4:119–122. [PubMed: 11875985] 
28. Khoshnood B, De Vigan C, Goffinet F, Leroy V. Prenatal screening and diagnosis of congenital 
toxoplasmosis: a review of safety issues and psychological consequences for women who undergo 
screening. Prenat Diagn. 2007; 27:395–403. [PubMed: 17380472] 
29. Cornu C, Bissery A, Malbos C, Garwig R, Cocherel C, Ecochard R, Peyron F, Wallon M. Factors 
affecting the adherence to an antenatal screening programme: an experience with toxoplasmosis 
screening in France. Euro Surveill. 2009; 14:21–25. [PubMed: 19317970] 
Davis et al. Page 9













30. Sagel U, Kremer A, Mikolajczyk RT. Incidence of maternal Toxoplasma infection in pregnancy in 
Upper Austria, 2000-2007. BMC Infect Dis. 2011; 11:348. [PubMed: 22168604] 
31. Toxoplasma gondii Antibodies, IgM, Quantitation; Toxoplasma gondii Antibodies, IgG.. The 
Healthcare Blue Book; www.healthcarebluebook.com. [2 February 2014]
32. Hedman K, Lappalainen M, Seppala I, Makela O. Recent primary Toxoplasma infection indicated 
by a low avidity of specific IgG. J Infect Dis. 1989; 159:736–740. [PubMed: 2926163] 
33. Hedman K, Lappalainen M, Seppala I, Makela O. Recent primary Toxoplasma infection indicated 
by a low avidity of specific IgG. J Infect Dis. 1989; 159:736–740. [PubMed: 2926163] 
34. Roberts A, Hedman K, Luyasu V, Zufferey J, Bessieres JH, Blatz RM, Candolfi E, Decoster A, 
Enders G, Gross U, Guy E, Hayde M, Ho-Yen D, Johnson J, Lecolier B, Naessens A, Pelloux H, 
Thulliez P, Petersen E. Multicenter evaluation of strategies for serodiagnosis of primary infection 
with Toxoplasma gondii. Eur J Clin Microbiol Infect Dis. 2001; 20:467–474. [PubMed: 
11561802] 
35. Cortina-Borja M, Tan HK, Wallon M, Paul M, Prusa A, Buffolano W, Malm G, Salt A, Freeman 
K, Petersen E, Gilbert RE, European Multicentre Study on Congenital Toxoplasmosis (EMSCOT). 
Prenatal treatment for serious neurological sequelae of congenital toxoplasmosis: an observational 
prospective cohort study. PLoS Med. 2010; 7:e1000351. [PubMed: 20967235] 
36. Gratzl R, Sodeck G, Platzer P, Jäger W, Graf J, Pollak A, Thalhammer T. Treatment of 
toxoplasmosis in pregnancy: concentrations of spiramycin and neospiramycin in maternal serum 
and amniotic fluid. Eur J Clin Microbiol Infect Dis. 2002; 21:12–16. [PubMed: 11913495] 
37. Desmonts, G.; Couvreur, J. Congenital toxoplasmosis: a prospective study of the offspring of 542 
women who acquired toxoplasmosis during pregnancy.. In: Thalhammer, O.; Pollak, A.; 
Baumgarten, K., editors. Perinatal medicine: proceedings of the 6th European Congress, Vienna. 
Thieme Publishers; Stuttgart, Germany: Georg: 1979. p. 51-60.
38. Forestier F. Les foetopathies infectieuses: prevention, diagnostic prenatal, attitude pratique. Presse 
Med. 1991; 20:1448–54. [PubMed: 1658769] 
39. Couvreur J, Desmonts G, Thulliez P. Prophylaxis of congenital toxoplasmosis: effects of 
spiramycin on placental infection. J Antimicrob Chemother. 1988; 22:193–200. [PubMed: 
3182443] 
40. Thiébaut R, Leroy V, Alioum A, Binquet C, Poizat G, Salmi LR, Gras L, Salamon R, Gilbert R, 
Chêne G. Biases in observational studies of the effect of prenatal treatment for congenital 
toxoplasmosis. Eur J Obstet Gynecol Reprod Biol. 2006; 124:3. [PubMed: 16140453] 
41. Foulon W, Villena I, Stray-Pedersen B, Decoster A, Lappalainen M, Pinon JM, Jenum PA, 
Hedman K, Naessens A. Treatment of toxoplasmosis during pregnancy: a multicenter study of 
impact on fetal transmission and children's sequelae at age 1 year. Am J Obstet Gynecol. 1999; 
180:410. [PubMed: 9988811] 
42. Gilbert RE, Gras L, Wallon M, Peyron F, Ades AE, Dunn DT. Effect of prenatal treatment on 
mother to child transmission of Toxoplasma gondii: retrospective cohort study of 554 mother-child 
pairs in Lyon, France. Int J Epidemiol. 2001; 30:1303. [PubMed: 11821334] 
43. Jones JL, Kruszon-Moran D, Wilson M, McQuillan G, Navin T, McAuley JB. Toxoplasma gondii 
Infection in the United States: Seroprevalence and Risk Factors. Am J Epidemiology. 2001; 
54:357–365.
Davis et al. Page 10















Davis et al. Page 11

























Davis et al. Page 12
TABLE 1
Demographic characteristics of respondents
Total (N = 267)
Question Answer n N % 95% CI
Gender Male 122 266 45.9 (39.9, 52.2)
Female 144 266 54.1 (48.0, 60.0)
Geographic area
Midwest 70 266 26.3 (20.9, 31.8)
Northeast 45 266 16.9 (12.7, 22.1)
South 88 266 33.1 (27.6, 39.2)
West 59 266 22.2 (17.4, 27.8)
Outside Continental US 4 266 1.5 (0.4, 3.8)
Practice location Urban: inner city 33 266 12.4 (8.7,16.0)
Urban: other 81 266 30.5 (25.1, 36.5)
Suburban 117 266 44.0 (37.7, 50.0)
Rural 35 266 13.2 (9.4, 17.9)
Military 0 266 0.0 -
Practice structure
Solo private practice 49 266 18.4 (13.9, 23.5)
Group practice 168 266 63.2 (56.8, 68.7)
University 34 266 12.8 (9.0, 17.3)
Hospital-based 8 266 3.0 (1.3, 5.8)
Other 8 266 3.0 (1.3, 5.8)
Specialty General OB/Gyn 233 266 87.6 (83.6, 91.5)
Gynecology only 15 266 5.6 (2.9, 8.4)
Obstetrics only 8 266 3.0 (1.3, 5.9)
Maternal-fetal Medicine 9 266 3.4 (1.2, 5.6)
Other 2 266 0.8 (0, 1.8)
Primary Race/Ethnicity served
White, non-Hispanic 183 266 68.8 (63.5, 74.6)
White, Hispanic 25 266 9.4 (5.9, 13.0)
Asian/Pacific Isl. 11 266 4.1 (1.8, 6.6)
Native American/Alaska native 1 266 0.4 (0.0, 1.1)
African-Amer., non-Hispanic 18 266 6.8 (3.8, 9.8)
African-Amer., Hispanic 6 266 2.3 (0.5, 4.1)
Multiracial 17 266 6.4 (3.5, 9.4)
unsure 4 266 1.5 (0.0, 2.3)
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TABLE 2




n N % 95% CI
CLINICAL
How often does a pregnant patient receive counseling in your 
practice about preventing acute T. gondii infection? (CHECK ALL 
THAT APPLY)
At the initial exam 197 267 73.8 (68.1, 79.0)
At every visit 0 267 0.0 _
When she asks questions 80 267 30.0 (24.5, 35.9)
When she mentions she was ill 20 267 7.5 (4.6, 11.3)
If I consider her at high risk 68 267 25.5 (20.4, 31.1)
Never 8 267 3.0 (1.3, 5.8)
Don't know 5 267 1.9 (0.6, 4.3)
Other 6 267 2.2 (0.4, 4.0)
For each exposure please indicate whether you consider it a risk 
factor and if so, whether your counseling includes it.
a) Changing cat litter without gloves
a Risk factor (RF) 250 263 95.1 (91.7, 97.3)
Counseled on 218 224 97.3 (94.3, 99.0)
b) Permitting a pet cat to go outdoors 
a Risk factor 201 251 80.1 (75.1, 85.0)
Counseled on 155 180 86.1 (80.2, 90.1)
c) Changing cat litter every few days (vs. daily)
a Risk factor 139 257 54.1 (47.8, 60.3)
Counseled on 86 121 71.1 (62.1, 79.0)
d) Petting a cat Risk factor 42 259 16.2 (11.9, 21.3)
Counseled on 27 35 77.1 (60.9, 90.0)
e) Having a litter of kittens at home 
a Risk factor 55 260 21.2 (16.4, 26.6)
Counseled on 26 40 65.0 (48.3, 79.4)
f) Contact with sand from an uncovered sandbox 
a Risk factor 198 251 78.9 (73.3, 83.8)
Counseled on 95 166 57.2 (49.3, 64.9)
g) Eating raw or undercooked meat
a Risk factor 219 263 83.3 (78.2, 87.6)
Counseled on 152 181 84.0 (77.8, 89.0)
h) Eating raw or undercooked oysters, mussels or clams 
a Risk factor 64 254 25.2 (20.0, 31.0)
Counseled on 35 48 72.9 (58.2, 84.7)
i) Handling raw meat without washing afterward 
a Risk factor 176 260 67.7 (61.6, 73.3)
Counseled on 91 145 62.8 (54.4, 70.6)
j) Eating unwashed raw fruits or vegetables 
a Risk factor 87 259 33.6 (27.9, 39.7)
Counseled on 52 74 70.3 (58.5, 80.3)
k) Gardening without gloves 
a Risk factor 160 260 61.5 (55.3, 67.5)
Counseled on 87 160 61.2 (56.2, 73.0)
l) Exposure to wild pigeon feces Risk factor 72 256 28.1 (22.7, 34.1)
Counseled on 20 57 35.1 (22.9, 48.9)
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Question Answer
Total
n N % 95% CI
m) Drinking untreated water from a stream, lake or pond
a Risk factor 94 257 36.6 (30.7, 42.8)
Counseled on 38 77 49.4 (37.8, 61.0)
n) Travelling to some foreign countries without taking food and 
water precautions 
a
Risk factor 165 261 63.2 (57.1, 69.1)
Counseled on 79 127 62.2 (53.2, 70.1)
o) Employment that involves soil exposure 
a Risk factor 149 260 57.3 (51.1, 63.4)
Counseled on 58 113 51.3 (41.7, 60.8)
p) Living in a home with a cockroach infestation Risk factor 28 261 10.7 (7.3, 15.1)
Counseled on 9 23 39.1 (19.7, 61.5)
How is counseling information provided? (CIRCLE ALL THAT 
APPLY):
Verbally by you 211 267 79.0 (73.7, 83.8)
Verbally by nurse 113 267 42.3 (36.3, 48.5)
Verbally by other office staff 19 267 7.1 (4.3, 10.9)
Pamphlet 44 267 16.5 (12.2, 21.5)
Which of the following laboratories would you use for T. gondii 
initial screening and confirmatory serologic testing if you felt they 
were indicated in a pregnant woman? (CHECK ALL THAT 
APPLY)
    a) Never request this type of serologic testing Initial 21 263 8.0 (4.7, 11.3)
Confirmatory 16 262 6.1 (3.5, 9.7)
    b) A local hospital lab Initial 115 263 43.7 (37.7, 49.7)
Confirmatory 62 262 23.7 (18.7, 29.3)
    c) A commercial lab (e.g., SKB, LabCorp) Initial 145 263 55.1 (48.9,61.3)
Confirmatory 91 262 34.7 (29.0, 40.1)
    d) State or local public health laboratory Initial 24 263 9.1 (5.9, 13.3)
Confirmatory 37 262 14.1 (10.1, 18.9)
    e) Palo Alto Research Institute Initial 5 263 1.9 (0.6, 4.4)
Confirmatory 29 262 11.1 (7.5, 15.5)
    f) Other Initial 3 262 1.1 (0.2, 3.3)
Confirmatory 5 262 1.9 (0.6, 4.4)
    g) Don't know Initial 16 263 6.1 (3.5, 9.7)
Confirmatory 22 262 8.4 (5.3, 12.4)
By total proportion of respondents: How do you decide whether to 
do serologic screening for acute T. gondii infection in 
asymptomatic pregnant women? (CIRCLE ONE): If other, what?
Do serologic screening in all 10 126 7.9 (3.9, 14.1)
Do serologic screening if there is 
no previous positive T. gondii IgG 
test
5 126 4.0 (1.3, 9.0)
Ask about exposures and/or 
symptoms; do serologic screening 
if present
70 126 55.6 (46.4, 64.4)
Ask about exposures and/or 
symptoms; do serologic screening 
if present AND there is no 
previous positive T. gondii IgG 
test
35 126 27.8 (20.2, 36.5)
Other patient request, in torch
b 
testing, ultrasound findings; state-
7 126 5.6 (2.3, 11.1)
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Question Answer
Total
n N % 95% CI
mandated in OR since 1977; if 
prior positive IGG flu titer
Which of the following would you use as a serologic test to 
confirm a screening result suggestive of acute T. gondii infection 
in a pregnant woman? (CIRCLE ALL THAT APPLY):
T. gondii IgG and IgM (+/− any 
other answer)
55 264 20.8 (16.1, 26.2)
T. gondii titer only 21 264 8.0 (5.0, 11.9)
Other 123 264 46.6 (40.5, 52.8)
Don't know 65 264 24.6 (19.4, 29.8)
If you were to make a diagnosis of acute maternal T. gondii 
infection in a pregnant woman AT 14 WEEKS gestation, which of 
the following would you do INITIALLY? (CIRCLE ALL THAT 
APPLY):
*
Make a presumptive diagnosis 31 264 11.7 (8.1, 16.3)
Begin antimicrobial therapy 38 264 14.4 (10.4, 19.2)
Perform amniocentesis for 
Toxoplasma PCR as soon as 
clinically safe to perform
20 264 7.6 (4.7, 11.5)
Perform amniocentesis for 
Toxoplasma PCR around 18 
weeks gestation
8 264 3.0 (1.3, 5.9)
Consult specialist 243 264 92.0 (88.1, 95.0)
Other 9 264 3.4 (1.6, 6.4)
Don't know 9 264 3.4 (1.6, 6.4)
If you were to make a diagnosis of acute maternal T. gondii 
infection in a pregnant woman AT 23 WEEKS gestation, which of 
the following would you do INITIALLY? (CIRCLE ALL THAT 
APPLY):
Make a presumptive diagnosis 39 264 14.8 (10.7, 19.6)
Begin antimicrobial therapy 22 257 8.6 (5.3, 12.3)
Perform amniocentesis for 
Toxoplasma PCR as soon as 
possible
25 264 9.5 (6.2, 13.7)
Consult with a specialist, e.g., in 
infectious disease or perinatology
247 264 93.6 (89.9, 96.2)
Other 6 264 2.3 (0.8, 4.9)
Don't know 7 264 2.7 (1.1, 5.4)
If you were to make a diagnosis of FETAL toxoplasmosis, after 
explaining the options, which of the following would you be most 
likely to recommend as INITIAL management? (CIRCLE ONE):
Antimicrobial treatment for 
toxoplasmosis
29 263 11.0 (7.5, 15.5)
Immediate fetal ultrasound 27 263 10.3 (6.9, 14.6)
Termination of pregnancy 2 263 0.8 (0.0, 2.7)
Consultation with an infectious 
disease specialist or perinatologist
222 263 84.4 (79.5, 88.6)
Do not make a recommendation, 
only explain options
8 263 3.0 (1.6, 6.4)
Other 4 263 1.5 (0.4, 3.9)
Don't know 7 263 2.7 (1.1, 5.4)
For each characteristic, circle the type of serologic test to which it 
applies. (CIRCLE ONE):
    Frequent false positives T. gondii IgG 16 253 6.3 (3.7, 10.2)
T. gondii IgM 
a 20 253 7.9 (4.7, 11.7)
Both 32 253 12.6 (9.0, 17.7)
Neither 28 253 11.1 (6.9, 14.9)
Not sure 157 253 62.1 (56.3, 68.7)
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Question Answer
Total
n N % 95% CI
    Frequent false negatives T. gondii IgG 4 254 1.6 (0.4, 4.1)
T. gondii IgM 11 254 4.3 (1.9, 7.2)
Both 24 254 9.4 (6.3, 14.0)
Neither
a 35 254 13.8 (9.6, 18.5)
Not sure 180 254 70.9 (65.2, 76.7)
    A true positive indicates infection within the past 3-6 months T. gondii IgG 15 252 6.0 (3.4, 9.7)
T. gondii IgM 108 252 42.9 (36.6, 49.2)
Both 41 252 16.3 (11.7, 21.1)
Neither
a 9 252 3.6 (1.7, 6.7)
Not sure 79 252 31.3 (25.9, 37.8)
    A true positive indicates infection within the past 12-18 months T. gondii IgG 73 245 29.8 (23.9, 35.7)
T. gondii IgM
a 16 245 6.5 (3.8, 10.4)
Both 37 245 15.1 (10.9, 20.3)
Neither 25 245 10.2 (6.7, 14.8)
Not sure 94 245 38.4 (32.4, 45.0)
    A true positive indicates infection at some point in the past
T. gondii IgG 
a 161 256 62.9 (56.9, 69.2)
T. gondii IgM 5 256 2.0 (0.7, 4.6)
Both 28 256 10.9 (7.6, 15.8)
Neither 1 256 0.4 (0.0, 2.2)
Not sure 58 256 22.7 (18.1, 28.9)
How effective do you believe treatment with spiramycin for a 
pregnant woman with acute T. gondii infection is in preventing 
congenital toxoplasmosis? (CIRCLE ONE):
Highly effective (70-100%) 28 263 10.6 (7.2, 15.0)
Moderately effective (40-70%) 56 263 21.3 (16.5, 26.8)
Somewhat effective (10-40%) 21 263 8.0 (5.0, 12.0)
Weakly effective or not effective 4 263 1.5 (0.4, 3.9)
Not known or controversial
a 19 263 7.2 (4.4, 11.1)
Don't know 135 263 51.3 (45.1, 57.5)
What does the Toxoplasma IgG avidity test help determine? 
(CIRCLE ONE):
*
Whether T. gondii infection 
occurred in the last 3-4 months
a
33 260 12.7 (8.9, 17.4)
Whether T. gondii infection 
occurred in the last 6-12 months
18 260 6.9 (4.2, 10.7)
Whether T. gondii infection 
actually occurred but not when it 
occurred
47 260 18.1 (13.6, 23.3)
Other: 2 260 0.8 (0.0, 2.8)
Don't know 160 260 61.5 (55.3, 67.5)
a
True risk factor for T. gondii transmission
b
Toxoplasmosis, Other (syphilis, varicella-zoster, parvovirus B19), Rubella, Cytomegalovirus (CMV), and Herpes.
*
Differences between CARN and non-CARN respondent answer distributions significant at p< .05; see text for description
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